-IPC EXAM STUDY GUIDE
A
PRACTICE TEST #2 2025-2026 |
Questions with Correct Solutions |
Advanced Infection Prevention &
Control | Pass Guaranteed - A+
Graded
ART A: MULTIPLE CHOICE (Questions 1–40)
P
Q1 (Surveillance & Epidemiology): A 450-bed tertiary care hospital reports 12 CLABSIs in 2024
among patients with 8,000 central line days. The NHSN standardized infection ratio (SIR) is
0.85 with a 95% confidence interval of 0.44–1.48. Which interpretation is most accurate?
A. The hospital's CLABSI rate is statistically significantly lower than the national benchmark.
B. The hospital should immediately implement an additional CLABSI prevention bundle.
C. The SIR suggests performance comparable to the national baseline; no significant difference
exists.
D. The raw rate of 1.5 per 1,000 line days exceeds the NHSN national average, indicating poor
performance.
[CORRECT] C
Rationale: Per NHSN methodology (CDC, 2024), an SIR of 1.0 represents performance equal to
the national baseline; the 95% CI (0.44–1.48) crosses 1.0, indicating no statistically significant
difference from expected. Option A is incorrect because the upper CI exceeds 1.0. Option B is
premature without statistical significance. Option D misinterprets raw rates without risk
adjustment—SIR is the preferred metric for inter-facility comparison. Clinical pearl: Always
examine confidence intervals before drawing performance conclusions; p-values alone are
insufficient in NHSN reporting.
Q2 (Pathogen Transmission): A patient in the ICU develops diarrhea 7 days after initiating
broad-spectrum cephalosporin therapy. C. difficile NAAT is positive, and the patient has 6
unformed stools in 24 hours. According to the 2024 CDC/SHEA guidance, which isolation
precaution is most appropriate?
A. Contact precautions for the duration of hospitalization plus 48 hours after diarrhea resolves.
B. Contact precautions for the duration of hospitalization only.
C. Contact precautions for 48 hours after diarrhea resolves, with discontinuation regardless of
hospitalization status.
, . Contact precautions for the duration of hospitalization plus 2 negative stool tests 24 hours
D
apart.
[CORRECT] A
Rationale: The 2024 CDC/SHEA C. difficile guidance maintains contact precautions for the
duration of hospitalization plus 48 hours after diarrhea resolves (defined as <3 unformed stools
in 24 hours). Option C incorrectly omits the in-hospital duration requirement. Option B omits the
post-resolution period during which shedding continues. Option D reflects outdated pre-2010
practice; test-of-cure is no longer recommended due to high false-positive rates from carrier
states. Clinical pearl: Extended contact precautions beyond 48 hours are not routinely
recommended but may be considered during outbreaks—document rationale if extended.
Q3 (Sterilization & Disinfection): A flexible bronchoscope requires high-level disinfection (HLD)
between patients. The automated endoscope reprocessor (AER) uses 2.4% glutaraldehyde with
a manufacturer-recommended minimum contact time of 20 minutes at 25°C. During a quality
audit, the IP notes the AER cycle completed in 18 minutes. What is the appropriate immediate
action?
A. Recall all patients scoped with the AER in the past 48 hours for retesting.
B. Quarantine the bronchoscope and reprocess using manual HLD for the full 20 minutes.
C. Accept the cycle as adequate since glutaraldehyde efficacy is time-independent above
minimum concentration.
D. Remove the AER from service, validate the cycle parameters, and reprocess all potentially
affected scopes.
[CORRECT] D
Rationale: Per ANSI/AAMI ST91 and FDA guidance, automated cycles must meet validated
parameters; an 18-minute cycle represents a process failure requiring immediate device
removal from service and reprocessing of all affected instruments. Option A is excessive without
evidence of infection transmission. Option B addresses only one scope while ignoring systemic
AER failure. Option C is dangerous—contact time is critical for HLD efficacy against
mycobacteria and spores. Clinical pearl: Always verify AER cycle printouts against validated
parameters; any deviation constitutes a "load failure" requiring full investigation per your facility's
sterilization quality assurance plan.
Q4 (Occupational Health): A nurse sustains a percutaneous injury from a hollow-bore needle
used on a patient with unknown HIV status. The source patient refuses HIV testing. According
to OSHA's Bloodborne Pathogens Standard (29 CFR 1910.1030) and 2024 USPHS guidelines,
which statement regarding post-exposure prophylaxis (PEP) is correct?
A. PEP should be initiated only after confirmed positive source HIV testing.
B. A 3-drug PEP regimen should be initiated immediately and continued for 4 weeks, with
source testing attempted via institutional policy.
C. A 2-drug PEP regimen is sufficient for all occupational HIV exposures regardless of exposure
severity.
D. PEP is not indicated without confirmed source HIV positivity; the nurse should receive only
HBV vaccine if non-immune.
[CORRECT] B
Rationale: USPHS 2024 guidelines recommend initiating a 3-drug PEP regimen (integrase
inhibitor + 2 NRTIs) as soon as possible after occupational exposure, ideally within 2 hours,
, ithout waiting for source testing results; source testing should be attempted per institutional
w
policy (state laws vary on testing without consent). Option A delays critical prophylaxis. Option C
is incorrect—3-drug regimens are recommended for all occupational exposures given the
potential for drug resistance. Option D contradicts OSHA requirements for immediate evaluation
and PEP consideration. Clinical pearl: Document the exposure within 1 hour, initiate PEP within
2 hours, and never delay PEP for source testing in high-risk exposures.
Q5 (Construction & Renovation): A hospital is renovating its hematology-oncology unit, creating
dust from drywall removal in an adjacent corridor. The unit houses neutropenic patients (ANC
<500). Per the 2024 FGI Guidelines and ASHE/ASHRAE standards, what is the minimum
required Infection Control Risk Assessment (ICRA) Class and barrier specification?
A. Class II; plastic sheeting taped at seams.
B. Class III; drywall barriers with sealed seams and negative air pressure.
C. Class IV; impermeable barriers, negative pressure, HEPA filtration, and dust mat
decontamination.
D. Class I; no special barriers required beyond standard construction signage.
[CORRECT] C
Rationale: Construction in adjacent spaces to high-risk patient care areas (hematology-oncology
with neutropenic patients) requires ICRA Class IV—the highest level—per FGI Guidelines
(2022) and ASHE standards: impermeable barriers, negative pressure relative to patient care
areas, HEPA-filtered exhaust, and dust mat decontamination at exits. Option A (Class II) is for
non-patient care areas with minimal dust. Option B (Class III) is for patient care areas without
immunocompromised patients. Option D is never appropriate for construction near patient care.
Clinical pearl: Verify negative pressure differentials (minimum -0.01 inches water column) with
daily smoke tube or digital manometer checks during active construction.
Q6 (Regulatory & Accreditation): During a Joint Commission survey, the IP is asked to
demonstrate compliance with IC.01.05.01 (managing IC risks during construction). Which
document should the IP present as primary evidence of proactive risk assessment?
A. The facility's annual infection prevention risk assessment.
B. The Infection Control Risk Assessment (ICRA) matrix completed before construction
commencement.
C. The engineering department's project timeline and budget.
D. The most recent CMS Conditions of Participation survey report.
[CORRECT] B
Rationale: Joint Commission standard IC.01.05.01 specifically requires an ICRA completed
before construction, renovation, or maintenance activities begin, using a multidisciplinary team
(IP, facilities, safety, nursing). Option A addresses general IP risks but not construction-specific
requirements. Option C demonstrates project management but not infection control risk
assessment. Option D is a regulatory survey report, not a proactive risk assessment tool.
Clinical pearl: The ICRA must be dated, signed by all team members, and include ongoing
monitoring documentation—surveyors will trace from pre-construction ICRA through project
completion.
Q7 (Quality Improvement): An IP is conducting a Failure Mode and Effects Analysis (FMEA) on
a new central line insertion protocol. The team identifies a potential failure: "line insertion without
maximal sterile barrier precautions." The team rates severity (S) = 8, occurrence (O) = 6, and
A
PRACTICE TEST #2 2025-2026 |
Questions with Correct Solutions |
Advanced Infection Prevention &
Control | Pass Guaranteed - A+
Graded
ART A: MULTIPLE CHOICE (Questions 1–40)
P
Q1 (Surveillance & Epidemiology): A 450-bed tertiary care hospital reports 12 CLABSIs in 2024
among patients with 8,000 central line days. The NHSN standardized infection ratio (SIR) is
0.85 with a 95% confidence interval of 0.44–1.48. Which interpretation is most accurate?
A. The hospital's CLABSI rate is statistically significantly lower than the national benchmark.
B. The hospital should immediately implement an additional CLABSI prevention bundle.
C. The SIR suggests performance comparable to the national baseline; no significant difference
exists.
D. The raw rate of 1.5 per 1,000 line days exceeds the NHSN national average, indicating poor
performance.
[CORRECT] C
Rationale: Per NHSN methodology (CDC, 2024), an SIR of 1.0 represents performance equal to
the national baseline; the 95% CI (0.44–1.48) crosses 1.0, indicating no statistically significant
difference from expected. Option A is incorrect because the upper CI exceeds 1.0. Option B is
premature without statistical significance. Option D misinterprets raw rates without risk
adjustment—SIR is the preferred metric for inter-facility comparison. Clinical pearl: Always
examine confidence intervals before drawing performance conclusions; p-values alone are
insufficient in NHSN reporting.
Q2 (Pathogen Transmission): A patient in the ICU develops diarrhea 7 days after initiating
broad-spectrum cephalosporin therapy. C. difficile NAAT is positive, and the patient has 6
unformed stools in 24 hours. According to the 2024 CDC/SHEA guidance, which isolation
precaution is most appropriate?
A. Contact precautions for the duration of hospitalization plus 48 hours after diarrhea resolves.
B. Contact precautions for the duration of hospitalization only.
C. Contact precautions for 48 hours after diarrhea resolves, with discontinuation regardless of
hospitalization status.
, . Contact precautions for the duration of hospitalization plus 2 negative stool tests 24 hours
D
apart.
[CORRECT] A
Rationale: The 2024 CDC/SHEA C. difficile guidance maintains contact precautions for the
duration of hospitalization plus 48 hours after diarrhea resolves (defined as <3 unformed stools
in 24 hours). Option C incorrectly omits the in-hospital duration requirement. Option B omits the
post-resolution period during which shedding continues. Option D reflects outdated pre-2010
practice; test-of-cure is no longer recommended due to high false-positive rates from carrier
states. Clinical pearl: Extended contact precautions beyond 48 hours are not routinely
recommended but may be considered during outbreaks—document rationale if extended.
Q3 (Sterilization & Disinfection): A flexible bronchoscope requires high-level disinfection (HLD)
between patients. The automated endoscope reprocessor (AER) uses 2.4% glutaraldehyde with
a manufacturer-recommended minimum contact time of 20 minutes at 25°C. During a quality
audit, the IP notes the AER cycle completed in 18 minutes. What is the appropriate immediate
action?
A. Recall all patients scoped with the AER in the past 48 hours for retesting.
B. Quarantine the bronchoscope and reprocess using manual HLD for the full 20 minutes.
C. Accept the cycle as adequate since glutaraldehyde efficacy is time-independent above
minimum concentration.
D. Remove the AER from service, validate the cycle parameters, and reprocess all potentially
affected scopes.
[CORRECT] D
Rationale: Per ANSI/AAMI ST91 and FDA guidance, automated cycles must meet validated
parameters; an 18-minute cycle represents a process failure requiring immediate device
removal from service and reprocessing of all affected instruments. Option A is excessive without
evidence of infection transmission. Option B addresses only one scope while ignoring systemic
AER failure. Option C is dangerous—contact time is critical for HLD efficacy against
mycobacteria and spores. Clinical pearl: Always verify AER cycle printouts against validated
parameters; any deviation constitutes a "load failure" requiring full investigation per your facility's
sterilization quality assurance plan.
Q4 (Occupational Health): A nurse sustains a percutaneous injury from a hollow-bore needle
used on a patient with unknown HIV status. The source patient refuses HIV testing. According
to OSHA's Bloodborne Pathogens Standard (29 CFR 1910.1030) and 2024 USPHS guidelines,
which statement regarding post-exposure prophylaxis (PEP) is correct?
A. PEP should be initiated only after confirmed positive source HIV testing.
B. A 3-drug PEP regimen should be initiated immediately and continued for 4 weeks, with
source testing attempted via institutional policy.
C. A 2-drug PEP regimen is sufficient for all occupational HIV exposures regardless of exposure
severity.
D. PEP is not indicated without confirmed source HIV positivity; the nurse should receive only
HBV vaccine if non-immune.
[CORRECT] B
Rationale: USPHS 2024 guidelines recommend initiating a 3-drug PEP regimen (integrase
inhibitor + 2 NRTIs) as soon as possible after occupational exposure, ideally within 2 hours,
, ithout waiting for source testing results; source testing should be attempted per institutional
w
policy (state laws vary on testing without consent). Option A delays critical prophylaxis. Option C
is incorrect—3-drug regimens are recommended for all occupational exposures given the
potential for drug resistance. Option D contradicts OSHA requirements for immediate evaluation
and PEP consideration. Clinical pearl: Document the exposure within 1 hour, initiate PEP within
2 hours, and never delay PEP for source testing in high-risk exposures.
Q5 (Construction & Renovation): A hospital is renovating its hematology-oncology unit, creating
dust from drywall removal in an adjacent corridor. The unit houses neutropenic patients (ANC
<500). Per the 2024 FGI Guidelines and ASHE/ASHRAE standards, what is the minimum
required Infection Control Risk Assessment (ICRA) Class and barrier specification?
A. Class II; plastic sheeting taped at seams.
B. Class III; drywall barriers with sealed seams and negative air pressure.
C. Class IV; impermeable barriers, negative pressure, HEPA filtration, and dust mat
decontamination.
D. Class I; no special barriers required beyond standard construction signage.
[CORRECT] C
Rationale: Construction in adjacent spaces to high-risk patient care areas (hematology-oncology
with neutropenic patients) requires ICRA Class IV—the highest level—per FGI Guidelines
(2022) and ASHE standards: impermeable barriers, negative pressure relative to patient care
areas, HEPA-filtered exhaust, and dust mat decontamination at exits. Option A (Class II) is for
non-patient care areas with minimal dust. Option B (Class III) is for patient care areas without
immunocompromised patients. Option D is never appropriate for construction near patient care.
Clinical pearl: Verify negative pressure differentials (minimum -0.01 inches water column) with
daily smoke tube or digital manometer checks during active construction.
Q6 (Regulatory & Accreditation): During a Joint Commission survey, the IP is asked to
demonstrate compliance with IC.01.05.01 (managing IC risks during construction). Which
document should the IP present as primary evidence of proactive risk assessment?
A. The facility's annual infection prevention risk assessment.
B. The Infection Control Risk Assessment (ICRA) matrix completed before construction
commencement.
C. The engineering department's project timeline and budget.
D. The most recent CMS Conditions of Participation survey report.
[CORRECT] B
Rationale: Joint Commission standard IC.01.05.01 specifically requires an ICRA completed
before construction, renovation, or maintenance activities begin, using a multidisciplinary team
(IP, facilities, safety, nursing). Option A addresses general IP risks but not construction-specific
requirements. Option C demonstrates project management but not infection control risk
assessment. Option D is a regulatory survey report, not a proactive risk assessment tool.
Clinical pearl: The ICRA must be dated, signed by all team members, and include ongoing
monitoring documentation—surveyors will trace from pre-construction ICRA through project
completion.
Q7 (Quality Improvement): An IP is conducting a Failure Mode and Effects Analysis (FMEA) on
a new central line insertion protocol. The team identifies a potential failure: "line insertion without
maximal sterile barrier precautions." The team rates severity (S) = 8, occurrence (O) = 6, and
